Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4212248 | 0.87 | KMT2A (0.60) | KMT2AMEN1SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL4215162 | 0.84 | KMT2A (0.52) | KMT2AMEN1SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL13878524 | 0.80 | KMT2A (0.46) | KMT2AMEN1SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL13878532 | 0.79 | ALDH1A1 (0.55) | KMT2AMEN1SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL13878529 | 0.79 | ALDH1A1 (0.55) | KMT2AMEN1SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL4224260 | 0.79 | ALDH1A1 (0.55) | KMT2AMEN1SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL1548732 | 0.78 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2ALDH1A1HSD11B1 | |
| SCHEMBL19173552 | 0.77 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL13878609 | 0.77 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL4212572 | 0.77 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1812407-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | Pfizer, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006048750-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | HSD11B1, HSD11B2, HSD17B11 | KMT2A 3107/4885MEN1 2198/4885SMN1; SMN2 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.